Exploring New Molecular Targets for Basal Cell Carcinoma Treatment Beyond Hedgehog Inhibitors

Basal cell carcinoma (BCC) is the most common skin cancer worldwide, primarily caused by excessive sun exposure and characterized by its slow growth and low metastatic potential. Traditionally, hedgehog (HH) pathway inhibitors, such as vismodegib and sonidegib, have been the mainstay of systemic therapy for advanced BCC. However, resistance to these treatments and the need for alternative therapeutic strategies have led researchers to explore new molecular targets. Understanding the Limitations of Hedgehog Inhibitors While hedgehog inhibitors have shown efficacy in treating advanced BCC, their use is not without drawbacks. Some patients experience disease recurrence or progression despite initial responsiveness to therapy. Additionally, the side effects associated with these medications can impact patient quality of life. As a result, there is a critical need to identify other molecular pathways that can be targeted for treatment. Emerging Molecular Targets for BCC Recent studies have highlighted several promising molecular targets beyond the hedgehog pathway: PI3K/Akt/mTOR Pathway: Dysregulation of the PI3K/Akt/mTOR signaling pathway has been implicated in various cancers, including BCC. Inhibition of this pathway may offer a new approach to treating BCC, particularly in patients who are resistant to hedgehog inhibitors. MAPK Pathway: The RAS/RAF/MEK/ERK pathway, commonly known as the MAPK pathway, is another target of interest. Genetic alterations in this pathway have been identified in BCC, suggesting that MAPK inhibitors could be effective in a subset of patients. Immune Checkpoint Inhibitors: Immunotherapy has revolutionized the treatment of several malignancies, and ongoing research is investigating its role in BCC. PD-1 and CTLA-4 inhibitors have shown promise in preliminary studies, potentially providing a new avenue for treatment. Wnt/β-catenin Pathway: This pathway plays a critical role in cell proliferation and differentiation. Modulation of Wnt signaling